Tags

Type your tag names separated by a space and hit enter

Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody.
J Dermatol. 2007 Jul; 34(7):473-6.JD

Abstract

Two women (aged 46 and 56 years) developed annular erythema on their sun-exposed skin, including their forearms and faces, after biweekly i.v. administration of paclitaxel for 3-4 months to treat breast cancer. Both cases showed interface changes of basal keratinocytes and high titers of serum anti-SSA/Ro antibody. The diagnoses of paclitaxel-induced cutaneous lupus erythematosus (LE) were made because the skin eruptions cleared rapidly within 3 weeks after the paclitaxel treatment was discontinued. Paclitaxel is proposed to be a causative agent that can provoke cutaneous LE.

Authors+Show Affiliations

Adachi A
Department of Dermatology, Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan. adc4954@ybb.ne.jp
Horikawa T
No affiliation info available

MeSH

Antibodies, AntinuclearAntineoplastic Agents, PhytogenicArmBreast NeoplasmsFemaleHumansLupus Erythematosus, CutaneousMiddle AgedPaclitaxelSjogren's SyndromeSkin

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

17584326

Citation

Adachi, Atsuko, and Tatsuya Horikawa. "Paclitaxel-induced Cutaneous Lupus Erythematosus in Patients With Serum anti-SSA/Ro Antibody." The Journal of Dermatology, vol. 34, no. 7, 2007, pp. 473-6.
Adachi A, Horikawa T. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol. 2007;34(7):473-6.
Adachi, A., & Horikawa, T. (2007). Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. The Journal of Dermatology, 34(7), 473-6.
Adachi A, Horikawa T. Paclitaxel-induced Cutaneous Lupus Erythematosus in Patients With Serum anti-SSA/Ro Antibody. J Dermatol. 2007;34(7):473-6. PubMed PMID: 17584326.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. AU - Adachi,Atsuko, AU - Horikawa,Tatsuya, PY - 2007/6/23/pubmed PY - 2007/9/26/medline PY - 2007/6/23/entrez SP - 473 EP - 6 JF - The Journal of dermatology JO - J Dermatol VL - 34 IS - 7 N2 - Two women (aged 46 and 56 years) developed annular erythema on their sun-exposed skin, including their forearms and faces, after biweekly i.v. administration of paclitaxel for 3-4 months to treat breast cancer. Both cases showed interface changes of basal keratinocytes and high titers of serum anti-SSA/Ro antibody. The diagnoses of paclitaxel-induced cutaneous lupus erythematosus (LE) were made because the skin eruptions cleared rapidly within 3 weeks after the paclitaxel treatment was discontinued. Paclitaxel is proposed to be a causative agent that can provoke cutaneous LE. SN - 0385-2407 UR - https://www.unboundmedicine.com/medline/citation/17584326/Paclitaxel_induced_cutaneous_lupus_erythematosus_in_patients_with_serum_anti_SSA/Ro_antibody_ DB - PRIME DP - Unbound Medicine ER -